International Journal of Women's Health
Open access peer-reviewed scientific and medical journals.
Dove Medical Press is now a member of the Open Access Initiative
An Author's Guide
A guide to help authors get their paper published.
Support Open Access and Dove Press
Promotional Article Monitoring - further details
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Treating dyspareunia caused by vaginal atrophy: a review of treatment options using vaginal estrogen therapy
(12024) Total Article Views
Authors: SA Kingsberg, S Kellogg, M Krychman
Published Date August 2009
Volume 2009:1 Pages 105 - 111
SA Kingsberg¹, S Kellogg², M Krychman³
1University Hospitals Case Medical Center, Case Western Reserve University Cleveland OH, USA; 2The Pelvic and Sexual Health Institute of Philadelphia, Drexel University College of Medicine, Philadelphia, USA; 3Southern California Center for Sexual Health and Survivorship Medicine, Newport Beach, CA, USA
Abstract: Vulvovaginal atrophy (VVA) and dryness are common symptoms of the decline in endogenous production of estrogen at menopause and often result in dyspareunia. Yet while 10% to 40% of women experience discomfort due to VVA, it is estimated that only 25% seek medical help. The main goals of treatment for vaginal atrophy are to improve symptoms and to restore vaginal and vulvar anatomic changes. Treatment choices for postmenopausal dyspareunia resulting from vulvovaginal atrophy will depend on the underlying etiology and might include individualized treatment. A number of forms of vaginal estrogen and manner of delivery are currently available to treat moderate to severe dyspareunia caused by VVA. They all have been shown to be effective and are often the preferred treatment due to the targeted efficacy for urogenital tissues while resulting in only minimal systemic absorption. Both healthcare professionals and patients often find it difficult to broach the subject of sexual problems associated with VVA. However, with minimal effort to initiate a conversation about these problems, healthcare providers can provide useful information to their postmenopausal patients in order to help them each choose the optimal treatment for their needs and symptoms.
Keywords: dyspareunia, postmenopausal vulvovaginal atrophy, vaginal estrogen therapy
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
Readers of this article also read:
"You do a tremendous job!!" Ruben Restrepo, University of Texas Health Science Center, San Antonio.
- Tinidazole in the treatment of bacterial vaginosis
- Antibacterial treatment of bacterial vaginosis: current and emerging therapies
- Contraceptive practices in Nigeria: Literature review and recommendation for future policy decisions
- Vaginal rings for delivery of HIV microbicides